Search Results - "Ralston, Stuart H."

Refine Results
  1. 1

    Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS by Tsourdi, Elena, Langdahl, Bente, Cohen-Solal, Martine, Aubry-Rozier, Bérengere, Eriksen, Erik Fink, Guañabens, Nuria, Obermayer-Pietsch, Barbara, Ralston, Stuart H., Eastell, Richard, Zillikens, M. Carola

    Published in Bone (New York, N.Y.) (01-12-2017)
    “…The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone…”
    Get full text
    Journal Article
  2. 2

    Management of Osteogenesis Imperfecta by Ralston, Stuart H, Gaston, Mark S

    Published in Frontiers in endocrinology (Lausanne) (11-02-2020)
    “…Osteogenesis imperfecta (OI) is the term used to describe a group of rare inherited skeletal disorders characterized by a greatly increased risk of fragility…”
    Get full text
    Journal Article
  3. 3

    Genetic regulation of bone mass and susceptibility to osteoporosis by Ralston, Stuart H, de Crombrugghe, Benoit

    Published in Genes & development (15-09-2006)
    “…Osteoporosis is a common disease with a strong genetic component characterized by reduced bone mass and increased risk of fragility fractures. Twin and family…”
    Get full text
    Journal Article
  4. 4

    Genetics of osteoporosis by Ralston, Stuart H.

    Published in Annals of the New York Academy of Sciences (01-04-2010)
    “…Osteoporosis is a common disease with a strong genetic component characterized by reduced bone mass and an increased risk of fragility fractures. Twin and…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Rare Inherited forms of Paget’s Disease and Related Syndromes by Ralston, Stuart H., Taylor, J. Paul

    Published in Calcified tissue international (01-05-2019)
    “…Several rare inherited disorders have been described that show phenotypic overlap with Paget’s disease of bone (PDB) and in which PDB is a component of a…”
    Get full text
    Journal Article
  7. 7

    Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta‐Analysis of Placebo‐Controlled Trials by Hald, Jannie D, Evangelou, Evangelos, Langdahl, Bente L, Ralston, Stuart H

    Published in Journal of bone and mineral research (01-05-2015)
    “…ABSTRACT Bisphosphonates are widely used off‐label in the treatment of patients with osteogenesis imperfecta (OI) with the intention of reducing the risk of…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Heavy cannabis use is associated with low bone mineral density and an increased risk of fractures by Sophocleous, Antonia, PhD, Robertson, Roy, MD, Ferreira, Nuno B., PhD, McKenzie, James, RGN, Fraser, William D., MD, Ralston, Stuart H., MD

    Published in The American journal of medicine (01-02-2017)
    “…Abstract Purpose To investigate possible associations between recreational cannabis use and bone health in humans. Methods Cross-sectional study of individuals…”
    Get full text
    Journal Article
  12. 12

    Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget’s Disease by Obaid, Rami, Wani, Sachin E., Azfer, Asim, Hurd, Toby, Jones, Ruth, Cohen, Philip, Ralston, Stuart H., Albagha, Omar M.E.

    Published in Cell reports (Cambridge) (10-11-2015)
    “…Paget’s disease of bone (PDB) is a common disease characterized by osteoclast activation that leads to various skeletal complications. Susceptibility to PDB is…”
    Get full text
    Journal Article
  13. 13

    Genetic Determinants of Paget’s Disease of Bone by Makaram, Navnit S., Ralston, Stuart H.

    Published in Current osteoporosis reports (01-06-2021)
    “…Purpose of Review To provide an overview of the role of genes and loci that predispose to Paget’s disease of bone and related disorders. Recent Findings…”
    Get full text
    Journal Article
  14. 14

    Combined deficiency of the Cnr1 and Cnr2 receptors protects against age‐related bone loss by osteoclast inhibition by Sophocleous, Antonia, Marino, Silvia, Kabir, Dilruba, Ralston, Stuart H., Idris, Aymen I.

    Published in Aging cell (01-10-2017)
    “…Summary The endocannabinoid system plays a role in regulating bone mass and bone cell activity and inactivation of the type 1 (Cnr1) or type 2 (Cnr2)…”
    Get full text
    Journal Article
  15. 15

    Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro by Staines, Katherine A., Myers, Katherine, Little, Kirsty, Ralston, Stuart H., Farquharson, Colin

    Published in Calcified tissue international (01-12-2021)
    “…Proton pump inhibitors (PPIs) have been associated with an increased risk of fragility fractures in pharmaco-epidemiological studies. The mechanism is unclear,…”
    Get full text
    Journal Article
  16. 16

    Insertion Mutation in Tnfrsf11a Causes a Paget's Disease–Like Phenotype in Heterozygous Mice and Osteopetrosis in Homozygous Mice by Alonso, Nerea, Wani, Sachin, Rose, Lorraine, van't Hof, Rob J., Ralston, Stuart H., Albagha, Omar M.E.

    Published in Journal of bone and mineral research (01-07-2021)
    “…ABSTRACT Early onset familial Paget's disease of bone (EoPDB), familial expansile osteolysis, and expansile skeletal hyperphosphatasia are related disorders…”
    Get full text
    Journal Article
  17. 17

    The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo by Idris, Aymen I, Landao-Bassonga, Euphemie, Ralston, Stuart H

    Published in Bone (New York, N.Y.) (01-04-2010)
    “…Abstract The vanilloid type 1 ion channel (TRPV1) is known to play an important role in the regulation of pain and inflammation. Pharmacological ligands of…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Cerebral Small Vessel Disease Burden Is Increased in Systemic Lupus Erythematosus by Wiseman, Stewart J, Bastin, Mark E, Jardine, Charlotte L, Barclay, Gayle, Hamilton, Iona F, Sandeman, Elaine, Hunt, David, Amft, E Nicole, Thomson, Susan, Belch, Jill F.F, Ralston, Stuart H, Wardlaw, Joanna M

    Published in Stroke (1970) (01-11-2016)
    “…BACKGROUND AND PURPOSE—Systemic lupus erythematosus (SLE) increases stroke risk, but the mechanism is uncertain. This study aimed to determine the association…”
    Get full text
    Journal Article
  20. 20

    Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta by Hald, Jannie D, Keerie, Catriona, Weir, Christopher J, Javaid, Muhammad K, Lam, Wayne, Osborne, Patricia, Walsh, Jennifer, Langdahl, Bente L, Ralston, Stuart H

    Published in BMJ open (22-11-2023)
    “…IntroductionOsteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis…”
    Get full text
    Journal Article